CA2055435A1 - Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii - Google Patents

Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii

Info

Publication number
CA2055435A1
CA2055435A1 CA002055435A CA2055435A CA2055435A1 CA 2055435 A1 CA2055435 A1 CA 2055435A1 CA 002055435 A CA002055435 A CA 002055435A CA 2055435 A CA2055435 A CA 2055435A CA 2055435 A1 CA2055435 A1 CA 2055435A1
Authority
CA
Canada
Prior art keywords
rna
retroviral vector
cell
stably transformed
foreign
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002055435A
Other languages
English (en)
Inventor
Eli Gilboa
Bruce Sullenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2055435A1 publication Critical patent/CA2055435A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
CA002055435A 1989-05-10 1990-05-10 Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii Abandoned CA2055435A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35417189A 1989-05-10 1989-05-10
PCT/US1990/002656 WO1990013641A1 (fr) 1989-05-10 1990-05-10 Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii
US354,171 1994-12-09

Publications (1)

Publication Number Publication Date
CA2055435A1 true CA2055435A1 (fr) 1990-11-11

Family

ID=23392147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002055435A Abandoned CA2055435A1 (fr) 1989-05-10 1990-05-10 Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii

Country Status (4)

Country Link
EP (1) EP0471796A4 (fr)
JP (1) JPH04505261A (fr)
CA (1) CA2055435A1 (fr)
WO (1) WO1990013641A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251675B1 (en) * 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
DE69233774D1 (de) 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
DE4225094A1 (de) * 1992-04-28 1993-11-04 Frank Andreas Harald Meyer Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
EP0596901B1 (fr) * 1992-05-27 2000-08-09 City Of Hope MOLECULES CHIMERIQUES DE RIBOZYMES D'ARNt LYS
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
AU5961994A (en) * 1993-01-22 1994-08-15 University Research Corporation Localization of therapeutic agents
US5670361A (en) * 1993-05-17 1997-09-23 The Regents Of The University Of California HIV-specific ribozymes
US6015661A (en) * 1994-02-14 2000-01-18 The Macfarlane Burnet Centre For Medical Research Limited Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
CA2183154A1 (fr) * 1994-02-14 1995-08-17 Nicholas John Deacon Souches non pathogenes de vih-1
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
WO1995027783A1 (fr) * 1994-04-06 1995-10-19 Joshi Sukhwal Sadna Inhibition de la multiplication du vih-1 dans des cellules de mammiferes
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
AU720359B2 (en) 1995-09-29 2000-06-01 Indiana University Research And Technology Corporation Methods for enhanced virus-mediated DNA transfer using molecules with virus- and cell-binding domains
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5955644A (en) * 1996-08-08 1999-09-21 M.D. Anderson Cancer Center Ku deficient cells and non-human transgenic animals
US6057489A (en) * 1996-09-12 2000-05-02 M.D. Anderson Cancer Center MmRad51-deficient cells and transgenic mice
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
EP3112468A1 (fr) 1998-05-15 2017-01-04 Genentech, Inc. Polypeptides allogéniques il-17 et utilisations thérapeutiques
CA2328496C (fr) 1998-05-15 2016-01-05 Genentech, Inc. Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci
EP1865061A3 (fr) 1998-05-15 2007-12-19 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE69932247T2 (de) 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
EP1978029A3 (fr) 1999-06-15 2008-10-15 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
NZ531141A (en) 1999-10-20 2005-07-29 Genentech Inc Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
CA2494705A1 (fr) 1999-12-01 2001-06-07 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
EP1897946B1 (fr) 1999-12-23 2012-07-11 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
ATE424457T1 (de) 2000-01-13 2009-03-15 Genentech Inc Menschliche stra6 polypeptide
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
CA2403809A1 (fr) 2000-03-22 2001-09-27 Curagen Corporation Proteines associees a l'angiogenese et acides nucleiques codant ces proteines
EP1944317A3 (fr) 2000-09-01 2008-09-17 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
WO2002096910A1 (fr) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (fr) 2001-06-20 2012-11-20 Genentech, Inc. Compositions et procedes destines au diagnostic et au traitement de tumeurs
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
WO2003057160A2 (fr) 2002-01-02 2003-07-17 Genentech, Inc. Compositions et methodes de diagnostic et de traitement d'une tumeur
DK1485477T3 (da) 2002-02-25 2009-08-10 Genentech Inc Hidtil ukendt type-1-cytokinreceptor GLM-R
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
EP2277908A3 (fr) 2003-07-08 2011-12-14 Genentech, Inc. Polypeptides hétérologues IL-14A/F, anticorps et utilisations thérapeutiques associées
EP1689432B1 (fr) 2003-11-17 2009-12-30 Genentech, Inc. Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
CN101175769A (zh) 2005-03-10 2008-05-07 健泰科生物技术公司 用于调控血管完整性的方法和组合物
EP1871163A2 (fr) 2005-06-06 2008-01-02 Genentech, Inc. Nouvelles interruptions geniques, compositions et methodes associees
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
US20080279868A1 (en) 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
CA2630432A1 (fr) 2005-11-21 2007-07-19 Genentech, Inc. Nouvelles dissociations de genes, compositions et procedes les concernant
CA2638821A1 (fr) 2006-02-17 2007-10-11 Genentech, Inc. Nouvelles disruption geniques, compositions et procedes associes
WO2007126455A2 (fr) 2006-04-05 2007-11-08 Genentech, Inc. Méthode d'utilisation du boc/cdo pour moduler l'émission des signaux du hedgehog
EP2082645A1 (fr) 2006-04-19 2009-07-29 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009102488A2 (fr) 2008-02-15 2009-08-20 Tufts University Modèle humanisé de la formation du complexe d’attaque membranaire (mac) sur la rétine murine et compositions, trousses et procédés de traitement de la dégénérescence maculaire
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
AU2010289400B2 (en) 2009-09-02 2014-10-23 Curis, Inc. Mutant smoothened and methods of using the same
RU2573896C2 (ru) 2009-10-15 2016-01-27 Дженентек, Инк. Химерные факторы роста фибробластов с измененной рецепторной специфичностью
CA2778442A1 (fr) 2009-10-22 2011-04-28 Genentech, Inc. Procedes et compositions pour moduler l'activation d'hepsine d'une proteine de stimulation de macrophage
CN102741294A (zh) 2009-11-30 2012-10-17 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
PE20130214A1 (es) 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
CA2843684A1 (fr) 2010-08-13 2012-02-16 Tufts University Compositions, trousses et methodes de traitement de la degenerescence maculaire au moyen de la proteine cd59 soluble independante de la membrane
WO2012047968A2 (fr) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened et ses procédés d'utilisation
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
JP6651506B2 (ja) 2014-08-28 2020-02-19 タフツ・ユニバーシティ 補体関連障害を処置するための組成物、方法およびキット
CA2975875A1 (fr) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened et methodes d'utilisation de celui-ci
WO2017136558A1 (fr) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened et méthodes d'utilisation dudit mutant
JP7430394B2 (ja) 2018-02-12 2024-02-13 トラスティーズ オブ タフツ カレッジ インフラマソームの活性化を阻害するためのｃｄ５９
WO2023089564A1 (fr) 2021-11-19 2023-05-25 Janssen Biotech, Inc. Méthode de traitement d'une atrophie géographique avec un vecteur de thérapie génique exprimant cd59 soluble

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
ES2090049T3 (es) * 1989-03-16 1996-10-16 Boehringer Ingelheim Int Unidades geneticas para la inhibicion de la funcion de arn.

Also Published As

Publication number Publication date
EP0471796A1 (fr) 1992-02-26
WO1990013641A1 (fr) 1990-11-15
JPH04505261A (ja) 1992-09-17
EP0471796A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
CA2055435A1 (fr) Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii
McBride et al. Position dependence of functional hairpins important for human immunodeficiency virus type 1 RNA encapsidation in vivo
Lee et al. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain
Dropulić et al. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression
Amendt et al. Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1
US5650309A (en) Viral vectors
Das et al. A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication
Sullenger et al. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication
Tabernero et al. The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function
JP2004532616A (ja) 二本鎖ｒｎａ仲介遺伝子抑制
WO1993011230A1 (fr) Cellule souche modifiee de mammifere bloquant la replication virale
JP2746480B2 (ja) 遺伝子発現に影響を与える多重標的応答因子をもつベクター
To et al. Inhibition of retroviral replication by anti-sense RNA
DE69534864T2 (de) Ribozyme gegen eine HIV Tat Sequenz
US20040253604A1 (en) RNA-mediated gene modulation
Gdovin et al. Molecular mechanisms of visna virus Tat: identification of the targets for transcriptional activation and evidence for a post-transcriptional effect
Berberich et al. Mutations in the regions of the Rous sarcoma virus 3'splice sites: implications for regulation of alternative splicing
WO1994016060A1 (fr) Mutants de vih destines a la suppression des infections par vih
JPS62501398A (ja) トリ赤芽球症ウイルスゲノムを含有するクロ−ニング又は発現ベクタ−及びそれらのベクタ−によりトランスフェクションされた細胞
Taylor et al. Interferon treatment inhibits the replication of simian immunodeficiency virus at an early stage: evidence for a block between attachment and reverse transcription
AU703964B2 (en) Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP0759936A1 (fr) Vecteurs a sequences tar multiples du vih-1 inhibant l'expression genique du vih-1
Korth et al. Interferon inhibits the replication of HIV-1, SIV, and SHIV chimeric viruses by distinct mechanisms
DE69333216T2 (de) Vektor, enthält ein bei ARN-Polymerase-III transcriptes Virus-Gen
Gelinas et al. Long-Term Expression of the Human ß-Globin Gene After Retroviral Transfer into Pluripotent Hematopoietic Stem Cells of the Mouse

Legal Events

Date Code Title Description
FZDE Dead